Rivafoli 5 Tablet contains Rivaroxaban 5 mg, an oral anticoagulant medicine used to help prevent and treat blood clots in various cardiovascular conditions. It works by selectively inhibiting Factor Xa, an important component in the blood clotting process, thereby reducing the formation of harmful clots within blood vessels. The medicine plays a significant role in modern anticoagulant therapy and is widely prescribed for long-term thromboembolic risk management.
Rivaroxaban helps maintain smooth blood flow by preventing excessive clot formation that may lead to serious complications such as stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Its targeted mechanism of action provides effective anticoagulation while offering the convenience of oral administration. The formulation is commonly used in patients requiring ongoing protection against clot-related cardiovascular events.
The tablet is frequently prescribed in conditions such as atrial fibrillation, venous thromboembolism, and postoperative thromboprophylaxis, depending on the clinical needs of the patient. Due to its predictable anticoagulant activity and established efficacy, Rivaroxaban has become an important therapeutic option in cardiovascular and vascular medicine. Regular medical supervision helps ensure safe and effective treatment outcomes.
With the growing prevalence of cardiovascular diseases and increasing awareness of thromboembolic risk management, Rivafoli 5 Tablet offers strong market potential in the cardiology segment. Its proven clinical utility, broad physician acceptance, and consistent demand in anticoagulant therapy make it a valuable product for retailers and distributors. The product presents excellent opportunities for sustainable growth within the cardiovascular pharmaceutical market.